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Abstract
A number of tools based on high-performance affinity separations have been developed
for studying drug-protein interactions. An example of one recent approach is ultrafast affinity
extraction. This method has been employed to examine the free (or non-bound) fractions of
drugs and other solutes in simple or complex samples that contain soluble binding agents. These
free fractions have also been used to determine the binding constants and rate constants for the
interactions of drugs with these soluble agents. This report describes the general principles of
ultrafast affinity extraction and the experimental conditions under which it can be used to
characterize such interactions. This method will be illustrated by utilizing data that have been
obtained when using this approach to measure the binding and dissociation of various drugs with
the serum transport proteins human serum albumin and alpha1-acid glycoprotein. A number of
practical factors will be discussed that should be considered in the design and optimization of
this approach for use with single-column or multi-column systems. Techniques will also be
described for analyzing the resulting data for the determination of free fractions, rate constants
and binding constants. In addition, the extension of this method to complex samples, such as
clinical specimens, will be considered.
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1.

Introduction
The extent of binding by many drugs to serum proteins can play a significant role in

determining the eventual activity and fate of these drugs in the circulation [1,2]. This makes the
measurement of a drug’s ability to bind to these proteins an important item to consider during the
discovery, development and use of a new pharmaceutical [2]. The binding of a drug with agents
in blood is often reversible and results in both bound and free fractions for the drug. Because the
bound form of a drug cannot usually cross a cell membrane or bind to a receptor, it is the free
fraction that often determines the overall activity of the drug [1-4]. Two serum proteins that bind
to a broad range of drugs are human serum albumin (HSA) and alpha1-acid glycoprotein (AGP,
or orosomucoid) [2]. More complex agents such as lipoproteins can also be involved in binding
to drugs in the circulation [5-11].
A number of techniques have been utilized to study and measure the binding of drugs
with serum proteins and other biological agents [2,7,12-33]. These methods have included
separation-based approaches such as equilibrium dialysis, ultrafiltration, liquid chromatography
and capillary electrophoresis. A number of spectroscopic methods have also been employed for
this work, such as absorbance, fluorescence, circular dichroism, nuclear magnetic resonance, and
surface plasmon resonance spectroscopy.

Differential scanning calorimetry and isothermal

titration calorimetry have been used as well for this purpose [2,7,12-33].
Another method that has been explored for studying drug-protein binding is high
performance affinity chromatography (HPAC) [1,3,34-40]. In HPAC, a biological binding agent
is used as a stationary phase for the isolation or analysis of components in a sample [1]. The
retention of injected or applied solutes in HPAC is based on the specific and reversible
interactions that occur in biological systems (e.g., drug-protein binding). This type of binding is
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combined in HPAC with supports such as silica particles or monolithic materials that have good
mass transfer properties and are capable of withstanding the pressures and flow rates that are
present in systems for high performance liquid chromatography [41].
HPAC has been used in a variety of formats to determine binding constants for drugprotein interactions, to study drug-solute competition for proteins, to characterize the binding
sites for these processes, and to describe the rates of these interactions [1,42]. Some advantages
of using HPAC for this type of work are its speed, precision, ability to be automated, and need
for only a small amount of a protein or binding agent. Other attractive features of HPAC are its
compatibility with many types of detectors, its good correlation with solution-based methods,
and its ability to often reuse the same immobilized binding agent for many samples [1,3,12,42].
Ultrafast affinity extraction is an HPAC technique that has been recently developed for
studying drug-protein binding [43-54]. Figure 1 illustrates the basis of this technique. This
method uses an affinity microcolumn to extract the free fraction of a drug from a sample on a
time scale that minimizes or allows controlled dissociation of the drug from its soluble binding
agents. This approach has been used to measure the free fractions of drugs and other solutes in
solute/protein mixtures and in biological samples [43-54]. The same method has also been used
to determine equilibrium constants and rate constants for drug-protein interactions [49,54].
This report will describe the general principles of ultrafast affinity extraction and various
factors to consider when using this method to characterize drug- or solute-protein interactions.
Practical aspects that will be considered will include the types of formats that can be used in this
method; factors to optimize when using this method for free fraction measurements; and
techniques for analyzing the resulting data to obtain equilibrium constants or rate constants.
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These items will be illustrated by using data that have been previously acquired by this method
for various drugs that are known to bind to HSA or AGP in serum or blood [44-46,52,53].

2.

Materials
The chemicals and biochemicals that are used in ultrafast affinity extraction should have

known purities and be obtained from sources that have good batch-to-batch reproducibilities for
these reagents. All buffers and aqueous solutions that are used in this method should be prepared
using deionized water, as obtained from water purification devices such as a Milli-Q Advantage
A10 system (Millipore, Billerica, MA, USA) or a NANOpure system (Barnstead, Dubuque, IA,
USA). The aqueous buffers and solutions employed in ultrafast affinity extraction should ideally
be filtered prior to injection or application to an HPLC system, such as by using 0.22 µm GNWP
nylon filters from Fisher Scientific (Pittsburgh, PA,USA) or comparable filtration devices.

2.1.

Solution and mobile phase preparation
The mobile phase used for ultrafast affinity extraction should mimic the pH and solution

composition of the biological system that is being examined [1].

For the study of drug

interactions with serum proteins, one common mobile phase that is used is 0.067 M potassium
phosphate buffer, pH 7.4 [42]. This buffer can be prepared by dissolving 7.546 g of monobasic
potassium phosphate and 37.724 g of dibasic potassium phosphate in 4.00 L water. The pH of
this solution can then be adjusted to 7.40 by the slow addition of low concentrations of either
hydrochloric acid or sodium hydroxide. After this buffer has been prepared and filtered, it
should be stored at 4ºC when not in use. Other buffers or solutions can also be used as the
mobile phase in ultrafast affinity extraction, depending on the nature of the system and types of
interactions that are to be characterized.
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The drug solutions to be used as standards or to be mixed with proteins should be ideally
prepared in the mobile phase and combined with a known amount of the protein or added to a
protein solution with a known concentration and that is prepared in the mobile phase. For
example, in work with propranolol, a stock solution of 100 μΜ propranolol can be prepared by
dissolving 2.95 mg of propranolol in 100 mL of a 0.067 M phosphate buffer, pH 7.4, and stirring
the solution overnight. This stock solution can be diluted with 0.067 M phosphate buffer, pH
7.4, to prepare a 1 μΜ standard solution. In examining the binding of this drug to AGP, a 4.1 mg
portion of AGP can be dissolved in 5 mL of the 1 µM propranolol working solution to give a
sample that contains 1 µM propranolol and 20 µM AGP. Other drug and protein combinations
can be used to make samples with alternative concentrations. Biological samples such as serum
that have a known volume can be spiked directly with a small volume of a solution that contains
a known concentration of the drug to be studied [52,53].
A sample/protein mixture that is used in ultrafast affinity extraction should be incubated
at the desired temperature for interaction studies (e.g., 37ºC for work under physiological
conditions) at least a half hour before it is used in any binding experiments. The individual drug
and protein solutions or remaining drug/mixture should be stored, when not in use, under
appropriate conditions to provide good stability for these reagents. For serum proteins, this often
involves storage of these solutions at 37ºC. However, the length of time over which such
solutions can be stored should be determined for each new drug or protein to ensure good
stability for these reagents is present over the course of the binding studies.
2.2.

Preparation of affinity microcolumns
Immobilized HSA or AGP was used as the stationary phase for the affinity microcolumns

in the examples provided in this report because of the ability of these serum proteins to undergo
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fast and reversible binding to a wide range of drugs, as well as their ability to later elute these
drugs under isocratic conditions at a physiological pH [1,48,50,55]. The affinity microcolumns
and columns that were used in these prior reports had a typical inner diameter of 2.1 mm and
lengths of 0.1-5.0 cm. However, other column dimensions can also be employed for ultrafast
affinity extraction as long as the total column residence times are suitable for isolation of a free
drug fraction. It was found for many drugs that the desired residence times are usually in the
range of approximately 0.1-0.9 s when using HSA or AGP as the soluble binding agent
[45,47,49,53,54].
A variety of supports can be used for HSA or AGP immobilization.

The specific

examples that were utilized in this report used Nucleosil Si-300-7 porous silica (7 μm particle
size, 300 Å pore size) from Macherey-Nagel (Duren, Germany). However, other types of porous
silica or even monolithic supports can also be modified for use in this type of work [56-58].
Many methods can be used to immobilize HSA onto porous silica or other types of HPLC
supports [47,56-58,59-62]. One common example of such a technique is the Schiff base method,
which is illustrated in Figure 2(a). In this method, a support such as silica is first converted into
or obtained in a diol-bonded form [58,59,60]. This form enables the support to have low nonspecific binding for many drugs and biological agents and makes this support easy to further
modify for the immobilization of proteins or other binding agents [59,60,63]. The diol groups
are then oxidized to aldehyde groups, which can be combined with primary amines on a protein
such as HSA to form a Schiff base. The Schiff base is then converted to a secondary amine upon
its formation by using sodium cyanoborohydride as a reducing agent. After immobilization has
taken place, sodium borohydride is often added to reduce any remaining aldehydes to form
alcohol groups [56,59,60].
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The following conditions can be used to immobilize HSA to Nucleosil Si-300-7 silica by
the Schiff base method. To make 0.10 g of HSA silica, 0.10 g of diol silica is first oxidized to
form aldehyde groups by placing this support into 2 mL of 90% acetic acid that contains 0.10 g
periodic acid.

This mixture is covered with aluminum foil and shaken for 2 h at room

temperature. The aldehyde-activated silica is then washed several times with water, followed by
washing with 0.10 M potassium phosphate buffer, pH 6.0. The aldehyde-activated silica is next
suspended in 0.5-1.0 mL of the 0.10 M phosphate buffer, pH 6.0, and combined with 10 mg
HSA and 23 mg sodium cyanoborohydride. This mixture is allowed to react, with gentle
shaking, for at least 3 days at 4ºC. The support is then washed several times with 0.10 M
phosphate buffer, pH 8.0, and suspended in 2-3 mL of this pH 8.0 buffer and combined with 2.5
mg sodium borohydride, which is added in three equal portions over 90 min while the mixture is
allowed to react at room temperature in a fume hood. The final support is washed with 0.5 M
sodium chloride in 0.10 M potassium phosphate buffer, pH 8.0, followed by further washing
with 0.067 M potassium phosphate buffer, pH 7.4. The support can be stored in the 0.067 M
phosphate buffer, pH 7.4, and at 4ºC until use. A control support can be prepared in the same
manner, but with no protein being added during the immobilization step [47-52].
Several methods have also been applied for immobilizing AGP onto HPLC-grade porous
silica [64-66]. The AGP support that was used in this particular study was prepared using
hydrazide-activated silica and mildly-oxidized AGP; this procedure has been shown to produce
immobilized AGP with drug binding properties that mimic those for soluble AGP [65,66]. This
hydrazide method is illustrated in Figure 2(b). In this immobilization scheme, silica is first
converted into or obtained in a diol-bonded form and oxidized with periodate to give an
aldehyde-activated form [65]. The aldehyde-activated silica is then reacted with an excess of
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oxalic dihydrazide to give hydrazide-activated support [65], with remaining aldehyde groups on
the support later being reduced by adding sodium borohydride. The hydrazide-activated support
is then combined with AGP that has undergone mild oxidation to produce aldehyde groups in its
carbohydrate chains, which can form a stable hydrazone bond with the support.
The following conditions can be used to immobilize AGP to Nucleosil Si-300-7 silica by
the hydrazide method [65]. To make 0.10 g of AGP silica, 0.10 g of diol silica is first oxidized
to form aldehyde groups by placing this support into 2 mL of 90% acetic acid that contains 0.10
g periodic acid. This mixture is covered with aluminum foil and shaken for 2 h at room
temperature. The aldehyde-activated silica is then washed several times with water.

The

aldehyde-activated silica is placed into 17.5 mL of a 0.10 M phosphate solution, pH 5.0, and
allowed to react for 2 h at room temperature with a five-fold mole excess of oxalic dihydrazide
versus the initial diol groups on the support (i.e., 1 mg/mL oxalic dihydrazide, in this case). The
support is then washed several times with 0.10 M phosphate buffer, pH 7.0. Any remaining
aldehyde groups on the support are reduced by adding 20 mL of 0.10 M potassium phosphate
buffer, pH 8.0, that contains a 25-fold mole excess of sodium borohydride versus the initial diol
groups, with this mixture being allowed to react for 90 min at room temperature in a fume hood.
The final support is washed with 0.10 M phosphate buffer, pH 7.0, before its use in the
immobilization of AGP [65].
To make 0.10 g of AGP silica, 10 mg of AGP is next dissolved in 2 mL of a 0.020 M
sodium acetate solution, pH 7.0, that also contains 0.15 M sodium chloride, according to the
literature for use in the mild oxidation of AGP [66]. This solution is combined in a 1:1 (v/v)
ratio with a solution that contains 20 mM periodic acid in the same buffer. This mixture is
covered in aluminum foil and allowed to react for 10 min in the dark at room temperature, with
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the reaction then being quenched by adding 0.25 mL of ethylene glycol per milliliter of solution.
These conditions result in approximately five aldehyde groups being generated per AGP [66].
The oxidized AGP can be purified by washing it with 0.10 M phosphate buffer, pH 7.0, in
centrifugal filtration devices [64], with the final volume of the AGP solution then being adjusted
to 2.0 mL with the same buffer. This solution of oxidized and purified AGP is mixed with 0.10 g
of hydrazide-activated silica, placed on an inversion shaker, and allowed to react for one week at
4ºC. The reaction is stopped by centrifuging the slurry, removing the supernatant, and washing
the support with 0.10 M phosphate buffer, pH 7.0. Any unreacted hydrazide groups that remain
on the support can be capped by adding a ~50-fold mol excess of glyceraldehyde versus the
support’s original hydrazide content, with this mixture being shaken for 6 h at 4ºC. The final
support is washed with 0.10 M phosphate buffer, pH 7.0, and stored in the same buffer at 4ºC
until further use [53,54]. A control support can be prepared in a similar manner but with no AGP
being added to the hydrazide-activated silica during the immobilization step.
In the examples that are cited in this report, microcolumns and columns with various
sizes (i.e., lengths of 1-50 mm and 2.1 mm i.d.) were used with the immobilized HSA and AGP
supports and control supports. For columns that had lengths of 5 mm or longer, the supports
were downward slurry packed into stainless steel columns. The packing pressure was usually
4,000 psi (or 28 MPa) for this type of column. For microcolumns that had lengths below 5 mm,
the supports were packed in a similar manner but instead used a frit-in-column design [67]. The
typical packing pressure for these shorter columns was 3,000 psi (20 MPa). Either set of packing
conditions used a neutral buffer such as 0.067 M phosphate buffer, pH 7.4, as the packing
solution, with the columns being stored at 4 °C in the same buffer when not in use.
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2.3.

Apparatus
Most standard HPLC systems can be adapted for use in ultrafast affinity extraction. For

the examples given in this report, a single-column chromatographic system for ultrafast affinity
extraction usually consisted of such components as a PU-2080 plus pump from Jasco (Easton,
MD, USA), a six-port LabPro valve from Rheodyne (Cotati, CA, USA), a Jasco UV-2075 UV
absorbance detector, a Jasco AS-2057 plus autosampler, and a Jasco CO-2067 plus column oven.
However, other types of pumps, detectors, autoinjectors and equipment for column temperature
control can also be employed for this type of system. The general design for this single-column
system is shown in Figure 3(a). During the binding experiments that were carried out for the
examples cited in this report, the temperature of the column oven was often maintained at 37 ºC,
although other temperature can also be utilized. The size used for the microcolumn in this
system will depend on the affinity of the injected drug/solute for the immobilized binding agent
and the flow rates that are to be used for isolation of the free drug/solute fraction [47,49-52].
However, microcolumn sizes in the range of 1-10 mm long and 2.1 mm I.D. have been used in
prior work with this approach, with this size tending to increase as the affinity of the injected
drug or solute decreases for the immobilized binding agent [48-53].
As is shown in going from Figure 3(a) to 3(b), the basic set up of a two-column system
for ultrafast affinity extraction and the equipment used in this system are similar to those for the
single-column system. The main additions are a second column, which is usually larger than the
first, and a six-port valve, which is used to place the second affinity column in line with the first
column. After elution of the non-retained peak from the first column, the position of the six-port
valve is switched to carry a portion of the retained peak from the first column and onto the
second affinity column. The components eluting from the second column are then monitored by
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a device such as an absorbance detector. This two-column approach can be used to provide a
higher level of resolution between the retained and non-retained drug fractions than can be
obtained when using only a single-column system [53]. Typical sizes for the second column in
this system have been 5-25 mm long and 2.1 mm I.D., with the column size that is needed again
tending to increase as the affinity of the drug/solute decreases for the immobilized binding agent
[48,50,52,53].
3.

Methods

3.1.

Optimization of ultrafast affinity extraction
The general scheme for the use of a single-column affinity system to measure free drug

fractions is shown in Figure 4(a) [54]. First, the drug and protein mixture is allowed to incubate
at the desired temperature prior to injection of this mixture onto an affinity microcolumn that
contains an immobilized binding agent for the drug (e.g., immobilized HSA or AGP). At low-tomoderate flow rates, some of the protein-bound drug in the sample will dissociate as the sample
passes through the microcolumn, as represented by the top portion of Figure 4(a).

This

dissociated drug increases the measured free drug fraction and provides data that can be used to
estimate the dissociation rate constant for the soluble drug-protein complex [54]. As the sample
passes through the microcolumn at a sufficiently high flow rate, only the original free fraction of
the drug is retained by the microcolumn as the soluble, bound form of the drug and excess
soluble protein are eluted as a non-retained peak. As is shown in the bottom portion of Figure
4(a), the free drug fraction that is measured under these conditions can be used to estimate the
actual or apparent equilibrium constant for the drug-protein interaction in solution.
Figure 4(a) shows how the residence time for a sample inside an affinity microcolumn
can play an important role when using ultrafast affinity extraction to measure free drug fractions
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[47,49,51-54]. This factor can be modulated by altering either the column size or flow rate
[47,49-52]. The effect of changing the flow rate during ultrafast affinity extraction is shown in
Figure 5. In this illustration, the apparent free fraction for a drug decreases as the flow rate is
increased from a low-to-moderate level and reaches a constant value at higher flow rate [54]. At
the low-to-moderate flow rates (i.e., less than 0.85 mL/min, in this example), some drug that was
bound to proteins in the sample is able to dissociate from these proteins, resulting in an increase
in the apparent free drug fraction. However, this apparent free drug fraction approaches the true
value when the flow rate becomes high enough to keep this dissociation at a negligible level.
The flow rate that is needed to obtain this condition will vary from one drug and protein system
to the next, but generally occurs when the sample residence time is on the order of a few hundred
milliseconds [47,49,51,53].
Figure 4(b) shows the general scheme for using ultrafast affinity extraction with a twocolumn system to measure free drug fractions [53]. In this case, an affinity microcolumn and
longer affinity column can be connected in series during part of the separation. The drug and
protein mixture is first injected onto only the affinity microcolumn, which will extract and retain
the free drug fraction from the sample while the bound form of the drug and excess soluble
protein elute as non-retained components [50,52,53]. For samples that are complex or that
contain a large amount of protein, baseline resolution may not always be obtained between the
retained and non-retained peaks of the first column. In this situation, a second and longer
affinity column can be placed online with the affinity microcolumn after most of the nonretained components have eluted. A part of the free drug fraction that is retained by the first
column is then delivered to the second column to enable further separation of the free drug
fraction from other sample components [50,52,53].
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One important factor to consider during this transfer process is the time that is used to
switch the second column online with the first [50,52,53]. The effect of varying this time on the
measured free drug fraction is illustrated in Figure 6 [53]. When the switching time is short, the
result is in an increase in the apparent free drug fraction due to contamination from non-retained
components in the sample, as shown in Figure 6(b). When the switching time is made longer,
this contamination is minimized and a consistent free drug fraction is observed. However, using
switching times that are too long will also create a loss in precision for the measured free drug
fraction as less of the retained peak enters the second column, as demonstrated in both Figures
6(a) and 6(b). As a result, use of an intermediate switching time is generally recommended to
provide both good accuracy and reasonable precision for the measured free drug fraction [53].

3.2.

Measurement of free drug fractions
The first way ultrafast affinity extraction can be used is to measure the free fraction of a

drug in a drug/protein mixture or more a complex sample that contains the drug and binding
agents [47]. Figure 7 shows some typical chromatograms from such a study, as obtained with an
HSA microcolumn and by using samples that contained the drug tolbutamide or a mixture of
tolbutamide and soluble HSA [50]. Once this type of separation has been optimized (i.e., as
described in the previous section for work at column residence times that minimize drug-protein
dissociation in the sample), the free drug fraction in the sample can be determined by dividing
the retained peak area observed for the drug by the total peak area that is measured for a standard
that contains the same total concentration of the drug but no protein [50,52,53]. It has been
demonstrated in several studies that good agreement is seen in the free fractions that are
measured under these conditions when compared to the results that are obtained by a reference
method such as ultrafiltration [45-48,52,53]. This method has also been employed in examining
14

systems that span a wide range of affinities (see Section 3.4), free fractions and free solute
concentrations. This has included free drug and hormone fractions that have ranged from 0.09%
to 92% [44,47,48,50,52], with precisions that are often comparable to or better than those
obtained by reference methods [44-48,53].

3.3.

Determination of rate constants
Another way ultrafast affinity extraction can be employed is to determine the dissociation

rate constant (kd) for a drug-protein complex. This can be accomplished by measuring the free
drug fraction at low-to-medium flow rates when a drug-protein mixture is injected onto the
affinity microcolumn [49]. The apparent free fractions are then measured, as described in the
previous section, and used to prepare a plot according to Eqs. (1) or (2) [49].
(1)
(2)
In these two equivalent equations, F0 is the true original free fraction of drug D in the sample
(e.g., as determined at high flow rates), and Ft is the apparent free fraction that is measured at
low-to-moderate flow rates (i.e., conditions where the drug-protein complex DP is allowed to
dissociate for time t in the microcolumn). According to Eqs. (1) and (2), plots made of either
ln[(1 – F0)/(1 - Ft)] or ln[1/(1 - Ft)] versus t should result in a linear relationship in which the
slope provides the dissociation rate constant kd for the complex of the drug with the soluble
protein [49].
Eq. (1) can be used when a direct and separate measurement can be made of F0, as
discussed in Section 3.2. As an alternative, Eq. (2) allows the value of F0 to instead be obtained
from the intercept of a plot of ln[1/(1 - Ft)] versus t. This second approach tends to provide a
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less precise estimate of F0 than when using a direct measurement of this parameter. However,
this second method can also be more useful for obtaining both F0 and kd in situations where
sufficiently high flow rates cannot be used with an affinity microcolumn to directly measure F0
[49].
Figure 8 shows some plots that are acquired when using Eqs. (1) and (2) for kinetic
studies, as based on data for the drug verapamil and soluble AGP [54]. Table 1 lists some
dissociation rate constants that have been obtained when using ultrafast affinity extraction with
either Eq. (1) or (2) to examine various drugs in the presence of soluble HSA or AGP [49,54].
The dissociation rate constants that have been measured by this method have ranged from 10-2 to
101 s-1, as have been obtained with systems with binding affinities spanning from 104 to 109 M-1
and with good agreement with literature values [12,49,51,52,70]. In the case of a binding agent
such as HSA that tends to have simple saturable interactions with drugs [49], consistent values
for dissociation rate constants have been acquired with this method when varying either the drug
or protein concentration that is used in the sample [49,51]. However, more complex binding
agents such as AGP have been found to have concentration-dependent values for their apparent
dissociation rate constants [54]. This latter effect has been proposed to be the result of a
combination of dissociation mechanisms that may be present in this type of drug/protein system
[54,68,69].

3.4.

Determination of binding constants
Use of a small column residence time can result in free drug fractions that can be

employed to estimate the equilibrium constant for a drug-protein interaction (e.g., as related to
the original free drug fraction in the initial sample).

For instance, a free fraction that is

determined under these conditions can be used with Eq. (3) to provide the association
16

equilibrium constant (Ka) for a drug-protein system that has a single-site, saturable interaction
[47].
(3)
In this equation, [A]0 and [P]0 are the total concentrations of the drug/analyte and soluble protein
in the injected sample, and F0 is the original free fraction of the drug/analyte in the sample at
equilibrium (i.e., as measured at a flow rate that minimizes drug-protein dissociation in the
column). The same general relationship can be used to estimate the global affinity constant
(nKa’) for a system in which there are multiple, independent and saturable interactions between a
drug and protein [47]. Although weaker, non-specific interactions may also make up part of
estimates for this global affinity constant, their contribution in most cases should be small when
compared to the contributions by higher affinity sites in the system. This last feature is reflected
by the good agreement that has been seen in several past studies between the global affinities that
are measured by this approach and those that have been obtained by other methods, as has been
noted for systems with affinities that have spanned from 103 – 109 M-1 [47-53].
Another method that can be used to estimate the equilibrium constants for drugs with
soluble proteins is based on the estimate of F0 that is obtained in kinetic studies when using Eq.
(2) [49]. In this approach, the value of F0 can be acquired from the intercept of a plot of ln[1/(1 Ft)] versus t, which can then be used along with Eq. (3) to find Ka or nKa’. Table 2 lists some
association equilibrium constants and global affinities that have been obtained in prior work
when using either of these methods for various drugs and soluble forms of HSA or AGP [49,54].
A more complex model, as described by Eqs. (4-6), can be used with ultrafast affinity
extraction and free fraction measurements to examine the interaction for a drug with two separate
binding agents. This type of model has been used to measure the association equilibrium
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constants or global affinities for a number of drugs in serum which can bind to both AGP and
HSA [53].
(4)

where,

(5)

(6)

In these equations Ka,A is the apparent or global affinity constant for a drug/analyte with AGP;
[D-A]eq is the equilibrium concentration for this drug’s complex with AGP; F is the measured
free drug fraction; [D]0, [A]0 and [H]0 are the original total sample concentrations of the drug,
AGP and HSA, respectively; [D-H]eq is the concentration of the drug’s complex with HSA; and
Ka,H is the association equilibrium constant or global affinity constant of drug with HSA [53].
Another model that has been used with free fraction analysis is a mixed-model, as
described by combining Eq. (3) and Eqs. (7-8). This particular model combines a non-saturable
process, as represented by Eq. (7), with saturable binding, as shown in Eq. (3), for systems that
may have both types of interactions present [54].
(7)
(8)
In these equations, [D] is the solution-phase concentration of the drug; [DP] is the concentration
of the same drug that has partitioned into the protein; KD is the distribution constant; CD is the
total concentration of the drug; Ka is the association equilibrium constant; and [P0] is again the
total concentration of the soluble protein [54].
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In general, a single-column system is usually sufficient to acquire an equilibrium constant
for a drug-protein system when the drug and protein are present at similar concentrations (e.g., if
the concentration of the protein is one- to two-times the drug’s concentration) [47,49,54]. A
two-column system is more commonly employed with complex samples or when there is a large
difference in the concentrations of the drug and protein [48,50,52,53]. Complex mixtures that
have been examined with two-column systems have included samples that contain more than one
form of a drug (e.g.,

drug enantiomers) [48], drug/protein mixtures that are prepared at

therapeutic or physiological concentrations, and drugs that are present in clinical samples [5052].
Ultrafast affinity extraction has been used in equilibrium studies for systems that have
varied from weak-to-strong binding [71]. For instance, this method has been used with affinity
columns containing antibodies to measure the free fraction of warfarin in samples containing a
mixture of this drug and HSA [43]. Ultrafast affinity extraction has also been utilized in
combination with flow-based displacement immunoassays to measure the free fractions of
thyroxine and phenytoin in clinical samples [44-46]. In addition, this method has been used to
measure the free fractions and equilibrium constants for various drugs with HSA/glycated HSA
[47,49,50,52] or AGP [53,54] and to study the interactions of testosterone with both HSA and
sex-hormone binding globulin [51].
4.

Conclusion
This report has described the method of ultrafast affinity extraction and has shown how

this approach can be employed as a tool for studying drug- or solute-protein interactions. The
general principles of this method were discussed, along with various experimental factors to
consider in the design and optimization of this technique and methods for analyzing the resulting
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data for equilibrium or kinetic studies.

Several applications for this approach were also

described. These applications included measurement of the free fractions for drugs and other
solutes in simple solutions or biological samples [43-54], and the use of this method to
characterize the equilibrium constants or rate constants for drug/solute-protein interactions [4354]. These applications and experimental considerations were illustrated by using data that have
been obtained through this method for various drugs and solutes that are known to bind to HSA
and AGP and with binding strengths that have ranged from 103 to 109 M-1 [44-46,52,53].
Several advantages for ultrafast affinity extraction have been noted in these applications.
For instance, this is a label-free method that can be used with a variety of detection techniques
[12]. Unlike other common approaches for biointeraction analysis (e.g., traditional HPAC and
surface plasmon resonance), this method allows for solute-protein binding to be examined
directly in solution, rather than between a solute and immobilized binding agent [12,49,51].
Other appealing features of this method include its ability to work with either low or high affinity
systems, its need for only a small amount of sample, and its ability to provide results in few
minutes after sample injection [12,52]. One current limitation of this method is that some
preliminary studies must be conducted to determine the correct column sizes and flow rates to
employed to extract the free solute fraction and separate it from non-retained sample components
[12,49,70]. However, this limitation is being overcome as more information and experience is
being obtained with this technique and further applications are being reported for this approach
[47-53]. This additional information and set of applications should, in turn, allow for even more
uses for this method in the future in areas that include biochemical or pharmaceutical research
and clinical analysis [12,44-53].
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5.

Notes

5.1.

The diol coverage of the modified Nucleosil Si-300 support that was used for the
examples cited in this report was around 300 µmol diol/g silica. This value may differ
when using other types of silica and will depend on the pore size and surface area of the
support [72,73].

5.2.

The degree of capture for a drug in ultrafast affinity extraction will vary with the flow
rate, amount of immobilized binding agent, and size of the affinity microcolumn. The
examples cited in this report typically had a capture efficiency of 95% or more when
using HSA and AGP microcolumns [47,49].

5.3.

When ultrafast affinity extraction is used with serum, these samples should be filtered
(e.g., twice using syringe filters with 0.2 µm nylon membranes) prior to their
combination with a drug or injection onto an HPLC system [52,53].

5.4.

Although some immobilization schemes can lead to non-specific interactions of a solute
to a support, it has been noted that this does not lead to any major effects in the
measurement of binding constants by ultrafast affinity extraction [53]. This is the case
because the affinity microcolumn is used only to capture and measure the free solute
fraction. The actual binding event that is examined is the solution-phase interaction of
the drug/solute with a soluble protein, and this process is not altered by non-specific
interactions due to the support [53].

5.5.

The protein content of the supports that were used here to illustrate the applications of
ultrafast affinity extraction were 22 mg AGP/g silica and 46-66 mg HSA/g silica [47-53].
The use of supports with smaller or larger protein contents may require the use of column
sizes that are slightly larger or smaller, respectively, than those used in these particular
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examples, as the protein content will affect the degree of retention and separation that is
obtained for the retained free drug fraction versus non-retained sample components [47].
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Figure legends
Figure 1. The general basis for ultrafast affinity extraction.

Figure 2. (a) The Schiff base method for the immobilization of HSA and (b) the hydrazide
method for the immobilization of AGP.

Figure 3. The typical designs for systems used in ultrafast affinity extraction based on (a) a
single-column or (b) a two-column system.

Figure 4. General approaches for the separation and analysis of free drug or solutes fractions by
using ultrafast affinity extraction using (a) a single-column system or (b) a twocolumn system.

Figure 5. Effect of injection flow rate on the column residence time (dashed line) and apparent
free drug fractions (solid line), as illustrated for 10 µL injections of samples
containing 1 µM propranolol and 20 µM soluble AGP onto a 2 mm × 2.1 mm i.d.
AGP microcolumn at pH 7.4 and 37 ºC. Reproduced with permission from Ref. [54].

Figure 6. Effect of changing the valve switching time in ultrafast affinity extraction when using
a two-column system.

These effects are illustrated for (a) the recovery of

carbamazepine at 0.5 mL/min on a 10 mm × 2.1 mm i.d. AGP column that was
placed on-line with a 5 mm × 2.1 mm i.d. AGP column at various times following the
injection of a 3 µL sample mixture of 15 µM carbamazepine/20 µM AGP/481 µM
HSA onto the first column at 3.0 mL/min, and (b) the apparent free drug fractions that
were measured by using the same chromatographic conditions and sample when
using a two-column system. All of the times show represent the elapsed interval after
34

sample injection. The error bars represent ± 1 standard error of the mean (n = 3) and
all the measurements were made at pH 7.4 and 37 ºC. Reproduced with permission
from Ref. [53].
Figure 7. Typical chromatograms obtained from the application of 185 μM tolbutamide
(therapeutic concentration) in the absence or presence of 526 μM HSA (physiological
concentration) onto a single 5 mm × 2.1 mm i.d. HSA microcolumn at 2.25 mL/min.
Reproduced with permission from Ref. [50].

Figure 8. Analysis of the interactions by verapamil with soluble AGP by using ultrafast affinity
extraction and Eqs. (1) and (2). The samples contained 10 µM verapamil and 20 µM
AGP. The error bars represent a range of ± 1 S.D. These results are based on data
from Ref. [54].
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Table 1.

Dissociation rate constants measured for various drugs with soluble HSA and
soluble AGP by using ultrafast affinity extraction on HSA and AGP
microcolumnsa
Dissociation rate constant, kd (s-1)

Drug and HSA

Estimate, Eq. (1)b

Estimate, Eq. (2)

Literature [Ref.]

Warfarin

0.80 (± 0.05)

0.72 (± 0.05)

0.41-2 [74-76]

Tolbutamide

0.59 (± 0.03)

0.58 (± 0.04)

0.49 (± 0.15) [75]

Acetohexamide

0.67 (± 0.03)

0.63 (± 0.03)

0.58 (± 0.02) [75]

Verapamil

0.35 (± 0.02)

0.36 (± 0.02)

0.38 (± 0.05) [77]

Gliclazide

0.61 (± 0.02)

0.59 (± 0.04)

Not reported

Chlorpromazine

3.96 (± 0.13)

3.35 (± 0.30)

Not reported

Drug and AGP

Estimate, Eq. (1)b

Estimate, Eq. (2)

Literature [Ref.]

0.62 (± 0.05)

0.59 (± 0.07)

Not reported

Lidocaine (15 µM:20 µM)

0.63 (± 0.05)

0.61 (± 0.05)

0.73 (± 0.07) [77]

Imipramine (3 µM:40

0.27 (± 0.04)

0.24 (± 0.04)

0.13 (± 0.01) [54]

0.29 (± 0.04)

0.28 (± 0.06)

0.38 (± 0.02) [54]

(drug:protein
concentrations)
Verapamil (10 µM:20
µM)

µM)
Disopyramide (3 µM:25
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µM)
Chlorpromazine (3 µM:40

0.60 (± 0.03)

0.56 (± 0.02)

0.10 (± 0.01) [54]

0.24 (± 0.02)

0.24 (± 0.02)

S-Propranolol

µM)
Propranolol (1 µM:20
µM)
0.19 (± 0.01) [54]

a

The values listed in this table are from Refs. [49,54]. All of the kd values obtained by ultrafast

affinity extraction were measured at pH 7.4 and 37 oC. The samples used in the binding studies
with HSA that contained 10 μM of a given drug and 20 μM HSA. In the work with AGP, the
drug and protein concentrations are given in the table. The values in the parentheses represent a
range of ± 1 S.D., as determined from the slopes of the best-fit lines constructed according to
Eqs. (1) and (2).
b

These values were found by using Eq. (1) when a point at the origin was included in the data

set.
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Table 2.

Equilibrium constants measured for various drugs with soluble HSA and AGP by
using ultrafast affinity extraction on HSA and AGP microcolumnsa
Association equilibrium constant, Ka,
or global affinity constant, nKa’ (M-1)

Drug and HSA

Estimate, Eq. (3)

Estimate, Eqs. (2-3)

Literature [Ref.]

Warfarin

2.4 (± 0.4) × 105

1.6 (± 0.2) × 105

2.0-5.7 × 105 [78-80]

Tolbutamide

1.1 (± 0.4) × 105

0.9 (± 0.2) × 105

1.1 (± 0.1) × 105 [81]b

Acetohexamide

1.8 (± 0.5) × 105

1.3 (± 0.1) × 105

1.7( ± 0.1) × 105 [82]b

Verapamil

1.5 (± 0.4) × 104

1.6 (± 0.2) × 104

1.4 ( ± 0.1) × 104
[83]c

Gliclazide

8.0 (± 0.6) × 104

6.9 (± 1.0) × 104

7.9 (± 0.1) × 104 [84]b

Chlorpromazine

6.2 (± 0.5) × 104

4.9 (± 0.5) × 104

6.4 × 104 [85]
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Drug and AGP

Literature [Ref.]

Estimate, Eq. (3)
Estimate, Eqs. (2-3)

(drug:protein
concentrations)
Verapamil (10 µM:20

1.2 (± 0.1) × 105

1.0 (± 0.2) × 105

1.2 × 105 [86,87]

1.1 (± 0.2) × 105

1.6 (± 0.4) × 105

1.1 – 1.7 (± 0.2) × 105

µM)
Lidocaine (10 µM:20 µM)

[88]
Imipramine (10 µM:20

1.5 (± 0.1) × 105

1.6 (± 0.4) × 105

1.4 – 1.7 × 105 [89,90]

6.9 (± 0.3) × 105

6.7 (± 1.1) × 105

6.3 × 105 [91]

5.4 (± 0.4) × 105

3.9 (± 0.8) × 105

4-17 × 105 [92,93]

2.9 (± 0.2) × 105

3.6 (± 0.8) × 105

3-14 × 105 [68,94]

µM)
Disopyramide (5 µM:7.5
µM)
Chlorpromazine (5 µM:10
µM)
Propranolol (5 µM:10
µM)

a

The values listed in this table are from Refs. [49,54]. Other conditions were the same as in

Table 1. The values in parentheses represent a range of ± 1 S.D., as determined by error
propagation.
b

c

The global affinity constants for these drugs were calculated from data in the given references.

This value represents the average association equilibrium constant for R- and S-verapamil at

their high affinity site on HSA.
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Highlights


Ultrafast affinity extraction is discussed as a method for studying drug-protein binding.



Various practical aspects are considered in the design and use of this approach.



This method is illustrated using data obtained various drugs with serum proteins.



Applications that are described include both kinetic and equilibrium studies.
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